Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3616-3621

  Luker, Tim ^a   Bonnert, Roger ^a   Schmidt, Jerzy ^a   Sargent, Carol ^a   Paine, Stuart W ^a   Thom, Stephen ^a   Pairaudeau, Gary ^a   Patel, Anil ^a   Mohammed, Rukhsana ^a   Akam, Elizabeth ^a   Dougall, Iain ^a   Davis, Andrew M ^a   Abbott, Phil ^a   Brough, Steve ^a   Millichip, Ian ^a   McInally, Thomas ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; CRTh2; DP2; Inflammation; Phenoxyacetic acid; Prostaglandin

Indexed keywords

CALCIUM ION; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS EXPRESSED ON TH2 LYMPHOCYTE AGONIST; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS EXPRESSED ON TH2 LYMPHOCYTE ANTAGONIST; IMMUNOLOGIC AGENT; PHENOXYACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM TRANSPORT; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; LIVER MICROSOME METABOLISM; NONHUMAN; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION;

ACETIC ACIDS; ANIMALS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; RATS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957851179     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.101     Document Type: Article

References (23)

1. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; Nagata, K. J. Exp. Med. 2001, 193, 255.
2. Nagata, K.; Hirai, H.; Tanaka, K.; Ogawa, K.; Aso, T.; Sugamura, K.; Nakamura, M.; Takano, S. FEBS Lett. 1999, 459, 195.
3. Xue, L.; Gyles, S. L.; Wettey, F. R.; Gazi, L.; Townsend, E.; Hunter, M. G.; Pettipher, R. J. Immunol. 2005, 175, 6531.
4. Pettipher, R.; Hansel, T. T. Drug News Perspect. 2008, 21, 317.
5. Norman, P. Expert Opin. Invest. Drugs 2010, 19, 947.
6. (a) Sugimoto, H.; Shichijo, M.; Okano, M.; Bacon, K. B. Eur. J. Pharmacol. 2005, 524, 30;
7. (b) Rosentreter, U.; Boshagen, H.; Seuter, F.; Perzborn, E.; Fiedler, V. B. Arzneim.-Forsch. 1989, 39, 1519;
8. (c) Shizuka, T.; Matsui, T.; Okamoto, Y.; Ohta, A.; Shichijo, M. Cardiovasc. Drug Rev. 2004, 22, 71;
9. (d) Aizawa, H.; Shigyo, M.; Nogami, H.; Hirose, T.; Hara, N. Chest 1996, 109, 338.
10. (a) Hata, A. N.; Lybrand, T. P.; Marnett, L. J.; Breyer, R. M. Mol. Pharmacol. 2005, 67, 640;
11. (b) Gervais, F. G.; Morello, J. P.; Beaulieu, C.; Sawyer, N.; Denis, D.; Greig, G.; Malebranche, A. D.; O'Neill, G. P. Mol. Pharmacol. 2005, 67, 1834;
12. (c) Birkinshaw, T. N.; Teague, S. J.; Beech, C.; Bonnert, R. V.; Hill, S.; Patel, A.; Reakes, S.; Sanganee, H.; Dougall, I. G.; Phillips, T. T.; Salter, S.; Schimdt, J.; Arrowsmith, E. C.; Carrillo, J. J.; Bell, F.; Paine, S. W.; Weaver, R. Bioorg. Med. Chem. Lett. 2006, 16, 4287;
13. (d) Crosignani, S.; Page, P.; Missotten, M.; Colovray, V.; Cleva, C.; Arrighi, J. F.; Atherall, J.; Macritchie, J.; Martin, T.; Humbert, Y.; Gaudet, M.; Pupowicz, D.; Maio, M.; Pittet, P. A.; Golzio, L.; Giachetti, C.; Rocha, C.; Bernardinelli, G.; Filinchuk, Y.; Scheer, A.; Schwarz, M. K.; Chollet, A. J. Med. Chem. 2008, 51, 2227.
14. Mimura, H.; Ikemura, T.; Kotera, O.; Sawada, M.; Tashiro, S.; Fuse, E.; Ueno, K.; Manabe, H.; Ohshima, E.; Karasawa, A.; Miyaji, H. J. Pharmacol. Exp. Ther. 2005, 314, 244.
15. (a) Sandham, D. A.; Aldcroft, C.; Baettig, U.; Barker, L.; Beer, D.; Bhalay, G.; Brown, Z.; Dubois, G.; Budd, D.; Bidlake, L.; Campbell, E.; Cox, B.; Everatt, B.; Harrison, D.; Leblanc, C. J.; Manini, J.; Profit, R.; Stringer, R.; Thompson, K. S.; Turner, K. L.; Tweed, M. F.; Walker, C.; Watson, S. J.; Whitebread, S.; Willis, J.; Williams, G.; Wilson, C. Bioorg. Med. Chem. Lett. 2007, 17, 4347;
16. (b) Ulven, T.; Receveur, J.-M.; Grimstrup, M.; Rist, Ø.; Frimurer, T. M.; Gerlach, L.-O.; Mathiesen, J. M.; Kostenis, E.; Uller, L.; Högberg, T. J. Med. Chem. 2006, 49, 6638.
17. Davis, A. M.; Keeling, D. J.; Steele, J.; Tomkinson, N. P.; Tinker, A. C. Curr. Top. Med. Chem. 2005, 5, 421.
18. 2 or test compound) and 80 μL of purified granulocytes. After incubation at 37 °C for 15 min, the cells were fixed and incubated in the dark for a further 15 min at room temperature. Remaining red blood cells were lysed using a hypotonic shock. The level of CD11b expression was determined by flow cytometry using lack of CD16 expression to distinguish eosinophils from neutrophils.
19. Bonnert, R. V.; Brough, S.; Davies, A.; Luker, T.; McInally, T.; Millichip, I.; Pairaudeau, G.; Patel, A.; Rasul, R.; Thom, S. PCT Int. Appl. WO2004089885, 2004; Chem. Abstr. 2004, 141, 366033.
20. At other biological targets, partial agonists or antagonists have had consistently higher lipophilicity than would be expected for an agonist of comparable affinity. See for example: Parker, M. A.; Kurrasch, D. M.; Nichols, D. E. Bioorg. Med. Chem. 2008, 16, 4661.
21. Dilute bovine serum albumin was used as part of the buffer medium for cost reasons. This is relatively commonplace (see for example Liu, J.; Fu, Z.; Wang, Y.; Schmitt, M.; Huang, A.; Marshall, D.; Tonn, G.; Seitz, L.; Sullivan, T.; Tang, H. L.; Collins, T.; Medina, J. Bioorg. Med. Chem. Lett. 2009, 19, 6419. ). At these dilute serum albumin concentrations and with relatively free compounds this approximation is expected to have minimal impact. However, significant differences between protein shifts across species can occur, and so independent plasma protein binding measurements in 100% plasma were undertaken for 34 across multiple species. Relatively consistent values were obtained: human 4.6, rat 5.6, dog 3.0, cyno 2.6 (% free)..
22. 3N requires C, 52.7; H, 4.5; N, 1.5; S, 7.8%. Found: C, 52.4; H, 4.5; N, 1.2; S, 7.8%.
23. Sargent, C.; Stinson, S.; Schmidt, J.; Dougall, I.; Bonnert, R.; Paine, S.; Saunders, M.; Foster, M. Br. J. Pharmacol. 2009, 98, pA2 online. (See https://bps.conference-services.net/resources/344/1686/pdf/JB2009-0098.pdf).